JP2008534568A5 - - Google Patents

Download PDF

Info

Publication number
JP2008534568A5
JP2008534568A5 JP2008503608A JP2008503608A JP2008534568A5 JP 2008534568 A5 JP2008534568 A5 JP 2008534568A5 JP 2008503608 A JP2008503608 A JP 2008503608A JP 2008503608 A JP2008503608 A JP 2008503608A JP 2008534568 A5 JP2008534568 A5 JP 2008534568A5
Authority
JP
Japan
Prior art keywords
compound
disorder
dihydro
alkyl
piperazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008503608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008534568A (ja
JP4318744B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/000655 external-priority patent/WO2006103511A1/en
Publication of JP2008534568A publication Critical patent/JP2008534568A/ja
Publication of JP2008534568A5 publication Critical patent/JP2008534568A5/ja
Application granted granted Critical
Publication of JP4318744B2 publication Critical patent/JP4318744B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2008503608A 2005-03-31 2006-03-21 シクロペンタピリジンおよびテトラヒドロキノリン誘導体 Expired - Fee Related JP4318744B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66718405P 2005-03-31 2005-03-31
US76215906P 2006-01-26 2006-01-26
PCT/IB2006/000655 WO2006103511A1 (en) 2005-03-31 2006-03-21 Cyclopentapyridine and tetrahydroquinoline derivatives

Publications (3)

Publication Number Publication Date
JP2008534568A JP2008534568A (ja) 2008-08-28
JP2008534568A5 true JP2008534568A5 (enExample) 2008-10-09
JP4318744B2 JP4318744B2 (ja) 2009-08-26

Family

ID=36218589

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008503608A Expired - Fee Related JP4318744B2 (ja) 2005-03-31 2006-03-21 シクロペンタピリジンおよびテトラヒドロキノリン誘導体

Country Status (24)

Country Link
US (1) US7507732B2 (enExample)
EP (1) EP1869000A1 (enExample)
JP (1) JP4318744B2 (enExample)
KR (1) KR100894006B1 (enExample)
AP (1) AP2007004144A0 (enExample)
AR (1) AR054021A1 (enExample)
AU (1) AU2006228378A1 (enExample)
BR (1) BRPI0609268A2 (enExample)
CA (1) CA2602348C (enExample)
CR (1) CR9386A (enExample)
DO (1) DOP2006000076A (enExample)
EA (1) EA200701853A1 (enExample)
GT (1) GT200600128A (enExample)
IL (1) IL185492A0 (enExample)
MA (1) MA29354B1 (enExample)
MX (1) MX2007012082A (enExample)
NL (1) NL1031473C2 (enExample)
NO (1) NO20074368L (enExample)
NZ (1) NZ560917A (enExample)
PE (1) PE20061333A1 (enExample)
TN (1) TNSN07367A1 (enExample)
TW (1) TW200722423A (enExample)
UY (1) UY29446A1 (enExample)
WO (1) WO2006103511A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1701943A1 (en) 2003-12-23 2006-09-20 Myogen, Inc. 5-ht2 receptors modulators, their pharmaceutical compositions and their use for the treatment of cardiovascular and muscle diseases
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
ATE496894T1 (de) * 2006-07-14 2011-02-15 Pfizer Prod Inc Tartratsalz von (7s)-7-ä(5-fluor-2-
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
WO2008068157A1 (en) * 2006-12-07 2008-06-12 F. Hoffmann-La Roche Ag 2-aminoquinolines as 5-ht(5a) receptor antagonists
JP5520051B2 (ja) 2007-11-15 2014-06-11 武田薬品工業株式会社 縮合ピリジン誘導体およびその用途
CN101959864A (zh) 2008-03-07 2011-01-26 弗·哈夫曼-拉罗切有限公司 2-氨基喹啉衍生物
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α7活化劑之用途
WO2011071136A1 (ja) 2009-12-11 2011-06-16 アステラス製薬株式会社 線維筋痛症治療剤
US8674218B2 (en) 2010-12-15 2014-03-18 General Electric Company Restraint system for an energy storage device
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
CN110236526B (zh) * 2019-06-28 2022-01-28 李秋 基于咀嚼吞咽动作及心电活动的摄食行为分析和检测方法
WO2024026423A1 (en) * 2022-07-27 2024-02-01 Black Diamond Therapeutics, Inc. Substituted quinoline derivatives as pi3k inhibitors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01211581A (ja) 1988-02-18 1989-08-24 Meiji Seika Kaisha Ltd シクロペンテノピリジン誘導体および抗潰瘍剤
US4985352A (en) 1988-02-29 1991-01-15 The Trustees Of Columbia University In The City Of New York DNA encoding serotonin 1C (5HT1c) receptor, isolated 5HT1c receptor, mammalian cells expressing same and uses thereof
EP0361489A3 (en) 1988-09-30 1991-06-12 Chugai Seiyaku Kabushiki Kaisha Novel 3,4-diaminoquinoline and pyridine compounds
DK0385237T3 (da) 1989-03-03 1994-07-25 Dainippon Pharmaceutical Co 2-(1-Piperazinyl)-4-phenylcycloalkanopyridinderivater, fremgangsmåde til fremstilling deraf og farmaceutisk præparat indeholdende dem
JP2660086B2 (ja) 1990-07-03 1997-10-08 明治製菓株式会社 脳及び心機能障害改善剤
JPH04103572A (ja) 1990-08-20 1992-04-06 Dainippon Pharmaceut Co Ltd 4―フェニル―2―(1―ピペラジニル)ピリジン誘導体
EP0572863A1 (de) 1992-06-05 1993-12-08 F. Hoffmann-La Roche Ag ZNS Pyrazinoindole
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
TW270114B (enExample) 1993-10-22 1996-02-11 Hoffmann La Roche
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
US5698766A (en) 1995-04-05 1997-12-16 The Regents Of The University Of California Transgenic animal model for testing drugs for treating eating disorders and epilepsy
TW477787B (en) 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
AU5343298A (en) 1997-01-13 1998-08-03 Yamanouchi Pharmaceutical Co., Ltd. 5-ht2c receptor agonists and aminoalkylindazole derivatives
PT863136E (pt) 1997-02-25 2004-01-30 Akzo Nobel Nv Derivados de azetidina e de pirrolidina
US6322738B1 (en) 1997-07-24 2001-11-27 Husky Injection Molding Systems Ltd. Method of injection over-molding articles
AU9810498A (en) 1997-10-24 1999-05-17 Neurogen Corporation 1-(2-naphthyl) and 1-(2-azanaphthyl)-4 -(1-phenylmethyl)piperazines being dopamine d4 receptor subtyp e ligands
US6040448A (en) 1997-10-24 2000-03-21 Neurogen Corporation Certain 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl) piperazines, dopamine receptor subtype specific ligands
AU4037699A (en) 1998-05-08 1999-11-29 Akzo Nobel N.V. Novel aryl-hydro naphthalenal kanamines
GB9819033D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds VI
GB9819035D0 (en) 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
GB9819020D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds III
JP2002523451A (ja) 1998-09-01 2002-07-30 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル抑制剤および方法
GB9819019D0 (en) 1998-09-01 1998-10-28 Cerebrus Ltd Chemical compounds II
JP2000191533A (ja) 1998-10-19 2000-07-11 Eisai Co Ltd 鎮痛剤
AU1738900A (en) 1998-11-19 2000-06-05 Nortran Pharmaceuticals Inc. Serotonin ligands as pro-erectile compounds
CA2361516A1 (en) 1999-01-27 2000-08-03 Jeffrey Thomas Mullaney Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
CA2374898C (en) 1999-05-21 2009-12-08 Biovitrum Ab Pyrazinyl-piperazine compounds, their use and preparation
AU2001279056A1 (en) * 2000-07-28 2002-02-13 Goodrich Corporation Optical waveguides and methods for making the same
SE0004245D0 (sv) * 2000-11-20 2000-11-20 Pharmacia Ab Novel compounds and their use
AU2426602A (en) 2000-11-20 2002-05-27 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
TWI245761B (en) 2001-03-01 2005-12-21 Telik Inc Antagonists of MCP-1 function and methods of use thereof
WO2002081443A1 (en) 2001-04-09 2002-10-17 Chiron Corporation Novel guanidino compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
CA2521619A1 (en) 2003-04-11 2004-10-28 Taigen Biotechnology Aminoquinoline compounds
US7101881B2 (en) 2003-06-11 2006-09-05 Pfizer Inc Tetrahydroquinolines
TW200612918A (en) 2004-07-29 2006-05-01 Threshold Pharmaceuticals Inc Lonidamine analogs

Similar Documents

Publication Publication Date Title
CA2602348A1 (en) Cyclopentapyridine and tetrahydroquinoline derivatives
JP6982376B2 (ja) Rorガンマ調節物質としての置換型テトラヒドロキノリン化合物
Ohashi et al. Discovery of the investigational drug TAK-441, a pyrrolo [3, 2-c] pyridine derivative, as a highly potent and orally active hedgehog signaling inhibitor: modification of the core skeleton for improved solubility
JP5522371B2 (ja) 化合物とその製造方法、および医薬組成物
AU2022217791A9 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
CA2870000C (en) Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JP2008044931A5 (enExample)
JP2012526735A5 (enExample)
EP2970125B1 (en) Substituted naphthyridine and quinoline compounds as mao inhibitors
JP2015527336A (ja) ピペラジノトリアゾール化合物及びその製造方法と製薬用途
CA2785923A1 (en) Therapeutic compounds and related methods of use
JP2010520264A5 (enExample)
TW200524928A (en) Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
TW201014849A (en) 1,2-disubstituted heterocyclic compounds
CN101268073A (zh) 杂环化合物、制备方法及其用途
JP6992109B2 (ja) mGluR2陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用
CN105722840B (zh) 作为PI3K、mTOR抑制剂的稠合喹啉化合物
KR20090120483A (ko) 혈관신생 저해제로서 스피로 치환된 화합물
KR920003981B1 (ko) 디아제핀 항알레르기 화합물
JP2012530129A5 (enExample)
KR20150119370A (ko) Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
JP2012502035A (ja) ロイコトリエン産生のインドリジン阻害剤
CN1332960C (zh) 作为腺苷a3受体配体的咪唑并喹啉衍生物
JP2007051155A5 (enExample)
CN1458933A (zh) 噻吩并嘧啶化合物及其盐以及其制备方法